Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16198660,Maximum inhibition,Maximum inhibition of factor Xa activity was achieved 1 to 4 hours after administration of BAY 59--7939 and ranged from 20% to 61% for the 5- to 80-mg doses.,"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198660/),%,20,26,DB06228,Rivaroxaban
,16198660,Maximum inhibition,Maximum inhibition of factor Xa activity was achieved 1 to 4 hours after administration of BAY 59--7939 and ranged from 20% to 61% for the 5- to 80-mg doses.,"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198660/),%,61,27,DB06228,Rivaroxaban
,30725221,oral clearance (CL/F),"The typical oral clearance (CL/F) was 6.12 L/h (relative standard error, 15.8%) and was associated with ABCB1 expression.",Downregulation of ABCB1 gene in patients with total hip or knee arthroplasty influences pharmacokinetics of rivaroxaban: a population pharmacokinetic-pharmacodynamic study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30725221/),[l] / [h],6.12,4161,DB06228,Rivaroxaban
,23535530,half-life,"Apixaban has a half-life of about 12 hours, and the normal dosage is 5 mg orally twice daily.",Apixaban: a new factor Xa inhibitor for stroke prevention in patients with nonvalvular atrial fibrillation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23535530/),h,12,8513,DB06228,Rivaroxaban
,25479967,Criv,Criv at 4 h was 186 ng/mL for patients taking 15 mg QD and 147 ng/mL for those taking 10 mg QD.,Anticoagulation intensity of rivaroxaban for stroke patients at a special low dosage in Japan. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25479967/),[ng] / [ml],186,11960,DB06228,Rivaroxaban
,25479967,Criv,Criv at 4 h was 186 ng/mL for patients taking 15 mg QD and 147 ng/mL for those taking 10 mg QD.,Anticoagulation intensity of rivaroxaban for stroke patients at a special low dosage in Japan. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25479967/),[ng] / [ml],147,11961,DB06228,Rivaroxaban
,28121368,area under plasma concentration-time curve,"Mean rivaroxaban area under plasma concentration-time curve, peak plasma concentration, time to peak plasma concentration and terminal half-life were 971.9 μg·h l-1 (coefficient of variation: 10.6), 135.3 μg l-1 (26.7), 1.5 h and 13.1 h (34.1) prior to and 1165.8 (21.9), 170.0 (15.9), 1.5 and 8.9 (44.6) postsurgery for SG patients and 933.7 μg·h l-1 (22.3), 136.5 μg l-1 (10.7), 1.5 h und 13.8 h (46.6) prior to and 1029.4 (7.4), 110.8 (31.8), 2.5 and 15 (60.0) postsurgery for Roux-en-Y gastric bypass patients, respectively.",Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28121368/),[h·μg] / [l],971.9,14252,DB06228,Rivaroxaban
,28121368,time to peak plasma concentration,"Mean rivaroxaban area under plasma concentration-time curve, peak plasma concentration, time to peak plasma concentration and terminal half-life were 971.9 μg·h l-1 (coefficient of variation: 10.6), 135.3 μg l-1 (26.7), 1.5 h and 13.1 h (34.1) prior to and 1165.8 (21.9), 170.0 (15.9), 1.5 and 8.9 (44.6) postsurgery for SG patients and 933.7 μg·h l-1 (22.3), 136.5 μg l-1 (10.7), 1.5 h und 13.8 h (46.6) prior to and 1029.4 (7.4), 110.8 (31.8), 2.5 and 15 (60.0) postsurgery for Roux-en-Y gastric bypass patients, respectively.",Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28121368/),,1165.8,14253,DB06228,Rivaroxaban
,28121368,terminal half-life,"Mean rivaroxaban area under plasma concentration-time curve, peak plasma concentration, time to peak plasma concentration and terminal half-life were 971.9 μg·h l-1 (coefficient of variation: 10.6), 135.3 μg l-1 (26.7), 1.5 h and 13.1 h (34.1) prior to and 1165.8 (21.9), 170.0 (15.9), 1.5 and 8.9 (44.6) postsurgery for SG patients and 933.7 μg·h l-1 (22.3), 136.5 μg l-1 (10.7), 1.5 h und 13.8 h (46.6) prior to and 1029.4 (7.4), 110.8 (31.8), 2.5 and 15 (60.0) postsurgery for Roux-en-Y gastric bypass patients, respectively.",Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28121368/),,1.5,14254,DB06228,Rivaroxaban
,28121368,terminal half-life,"Mean rivaroxaban area under plasma concentration-time curve, peak plasma concentration, time to peak plasma concentration and terminal half-life were 971.9 μg·h l-1 (coefficient of variation: 10.6), 135.3 μg l-1 (26.7), 1.5 h and 13.1 h (34.1) prior to and 1165.8 (21.9), 170.0 (15.9), 1.5 and 8.9 (44.6) postsurgery for SG patients and 933.7 μg·h l-1 (22.3), 136.5 μg l-1 (10.7), 1.5 h und 13.8 h (46.6) prior to and 1029.4 (7.4), 110.8 (31.8), 2.5 and 15 (60.0) postsurgery for Roux-en-Y gastric bypass patients, respectively.",Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28121368/),,8.9,14255,DB06228,Rivaroxaban
,28121368,terminal half-life,"Mean rivaroxaban area under plasma concentration-time curve, peak plasma concentration, time to peak plasma concentration and terminal half-life were 971.9 μg·h l-1 (coefficient of variation: 10.6), 135.3 μg l-1 (26.7), 1.5 h and 13.1 h (34.1) prior to and 1165.8 (21.9), 170.0 (15.9), 1.5 and 8.9 (44.6) postsurgery for SG patients and 933.7 μg·h l-1 (22.3), 136.5 μg l-1 (10.7), 1.5 h und 13.8 h (46.6) prior to and 1029.4 (7.4), 110.8 (31.8), 2.5 and 15 (60.0) postsurgery for Roux-en-Y gastric bypass patients, respectively.",Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28121368/),,1029.4,14256,DB06228,Rivaroxaban
,28121368,terminal half-life,"Mean rivaroxaban area under plasma concentration-time curve, peak plasma concentration, time to peak plasma concentration and terminal half-life were 971.9 μg·h l-1 (coefficient of variation: 10.6), 135.3 μg l-1 (26.7), 1.5 h and 13.1 h (34.1) prior to and 1165.8 (21.9), 170.0 (15.9), 1.5 and 8.9 (44.6) postsurgery for SG patients and 933.7 μg·h l-1 (22.3), 136.5 μg l-1 (10.7), 1.5 h und 13.8 h (46.6) prior to and 1029.4 (7.4), 110.8 (31.8), 2.5 and 15 (60.0) postsurgery for Roux-en-Y gastric bypass patients, respectively.",Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28121368/),,110.8,14257,DB06228,Rivaroxaban
,28121368,terminal half-life,"Mean rivaroxaban area under plasma concentration-time curve, peak plasma concentration, time to peak plasma concentration and terminal half-life were 971.9 μg·h l-1 (coefficient of variation: 10.6), 135.3 μg l-1 (26.7), 1.5 h and 13.1 h (34.1) prior to and 1165.8 (21.9), 170.0 (15.9), 1.5 and 8.9 (44.6) postsurgery for SG patients and 933.7 μg·h l-1 (22.3), 136.5 μg l-1 (10.7), 1.5 h und 13.8 h (46.6) prior to and 1029.4 (7.4), 110.8 (31.8), 2.5 and 15 (60.0) postsurgery for Roux-en-Y gastric bypass patients, respectively.",Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28121368/),,2.5,14258,DB06228,Rivaroxaban
,31514543,flow rate,"Chromatographic separations were achieved using Gemini C18, 150 mm × 4.6 mm, 5 µm, column eluted at flow rate of 1.5 mL/min with mobile phase (acetonitrile: ammonium acetate buffer (80:20 v/v)).",Liquid chromatography-tandem mass spectrometry method for determination of rivaroxaban in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31514543/),[ml] / [min],1.5,15987,DB06228,Rivaroxaban
,31514543,overall run time,The overall run time of method was about 1.8 min with elution times of Rivaroxaban and its internal standard Rivaroxaban D4 at around 1.18 min.,Liquid chromatography-tandem mass spectrometry method for determination of rivaroxaban in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31514543/),min,1.8,15988,DB06228,Rivaroxaban
,31514543,elution times,The overall run time of method was about 1.8 min with elution times of Rivaroxaban and its internal standard Rivaroxaban D4 at around 1.18 min.,Liquid chromatography-tandem mass spectrometry method for determination of rivaroxaban in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31514543/),min,1.18,15989,DB06228,Rivaroxaban
,31514543,m/z,"The multiple reaction monitoring transitions were set at 436/145 (m/z) and 440/145 (m/z) for Rivaroxaban and Rivaroxaban D4, respectively.",Liquid chromatography-tandem mass spectrometry method for determination of rivaroxaban in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31514543/),,436,15990,DB06228,Rivaroxaban
,31514543,m/z,"The multiple reaction monitoring transitions were set at 436/145 (m/z) and 440/145 (m/z) for Rivaroxaban and Rivaroxaban D4, respectively.",Liquid chromatography-tandem mass spectrometry method for determination of rivaroxaban in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31514543/),,440,15991,DB06228,Rivaroxaban
,31514543,m/z,"The multiple reaction monitoring transitions were set at 436/145 (m/z) and 440/145 (m/z) for Rivaroxaban and Rivaroxaban D4, respectively.",Liquid chromatography-tandem mass spectrometry method for determination of rivaroxaban in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31514543/),,145,15992,DB06228,Rivaroxaban
>,31514543,Extraction recoveries,Extraction recoveries were >88% for both rivaroxaban and its stable labeled internal standard rivaroxaban D4.,Liquid chromatography-tandem mass spectrometry method for determination of rivaroxaban in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31514543/),%,88,15993,DB06228,Rivaroxaban
,31215111,peak height (-TM) (C50 ),"Mean rivaroxaban concentrations halving the baseline value of ETP and peak height (-TM) (C50 ) were of 284 and 33.2 ng/mL, respectively: +TM, C50 declined to 19.4 and 13.8 ng/mL, reflecting a powerful inhibitory effect.",Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31215111/),[ng] / [ml],284,20123,DB06228,Rivaroxaban
,31215111,peak height (-TM) (C50 ),"Mean rivaroxaban concentrations halving the baseline value of ETP and peak height (-TM) (C50 ) were of 284 and 33.2 ng/mL, respectively: +TM, C50 declined to 19.4 and 13.8 ng/mL, reflecting a powerful inhibitory effect.",Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31215111/),[ng] / [ml],33.2,20124,DB06228,Rivaroxaban
,31215111,C50,"Mean rivaroxaban concentrations halving the baseline value of ETP and peak height (-TM) (C50 ) were of 284 and 33.2 ng/mL, respectively: +TM, C50 declined to 19.4 and 13.8 ng/mL, reflecting a powerful inhibitory effect.",Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31215111/),[ng] / [ml],19.4,20125,DB06228,Rivaroxaban
,31215111,C50,"Mean rivaroxaban concentrations halving the baseline value of ETP and peak height (-TM) (C50 ) were of 284 and 33.2 ng/mL, respectively: +TM, C50 declined to 19.4 and 13.8 ng/mL, reflecting a powerful inhibitory effect.",Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31215111/),[ng] / [ml],13.8,20126,DB06228,Rivaroxaban
,29376194,concentrations,Rivaroxaban concentrations ranged from <LLOQ to 300.6 ng/ml at the time of admission to hospital and from <LLOQ to 55.5 ng/ml at the beginning of the procedure.,Residual rivaroxaban exposure after discontinuation of anticoagulant therapy in patients undergoing cardiac catheterization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29376194/),ng,300,21279,DB06228,Rivaroxaban
,29376194,concentrations,Rivaroxaban concentrations ranged from <LLOQ to 300.6 ng/ml at the time of admission to hospital and from <LLOQ to 55.5 ng/ml at the beginning of the procedure.,Residual rivaroxaban exposure after discontinuation of anticoagulant therapy in patients undergoing cardiac catheterization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29376194/),ng,55,21280,DB06228,Rivaroxaban
,29376194,Times,Times since last rivaroxaban intake were (mean ± SD) 51.0 ± 31.7 h (admission) and 85.5 ± 36.8 h (start catheterization).,Residual rivaroxaban exposure after discontinuation of anticoagulant therapy in patients undergoing cardiac catheterization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29376194/),h,51.0,21281,DB06228,Rivaroxaban
,29376194,Times,Times since last rivaroxaban intake were (mean ± SD) 51.0 ± 31.7 h (admission) and 85.5 ± 36.8 h (start catheterization).,Residual rivaroxaban exposure after discontinuation of anticoagulant therapy in patients undergoing cardiac catheterization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29376194/),h,85.5,21282,DB06228,Rivaroxaban
,30411284,Elimination half-lives,Elimination half-lives could be estimated in eight patients and ranged between 14.6 and 59.7 h (median 21.6).,Serum Concentrations and Elimination Rates of Direct-Acting Oral Anticoagulants (DOACs) in Older Hip Fracture Patients Hospitalized for Surgery: A Pilot Study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30411284/),h,21.6,22073,DB06228,Rivaroxaban
,30411284,waiting time for,The observed waiting time for surgery was longer for patients using DOACs than warfarin (median 44 vs. 25 h).,Serum Concentrations and Elimination Rates of Direct-Acting Oral Anticoagulants (DOACs) in Older Hip Fracture Patients Hospitalized for Surgery: A Pilot Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30411284/),h,44,22074,DB06228,Rivaroxaban
,30411284,waiting time for,The observed waiting time for surgery was longer for patients using DOACs than warfarin (median 44 vs. 25 h).,Serum Concentrations and Elimination Rates of Direct-Acting Oral Anticoagulants (DOACs) in Older Hip Fracture Patients Hospitalized for Surgery: A Pilot Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30411284/),h,25,22075,DB06228,Rivaroxaban
,31898270,%EE,"The optimized RXB-PLGA-NPs (F8) with composition, PLGA (125 mg), PVA (0.5%w/w) and RXB (20 mg) was found optimum with particle size (496 ± 8.5 nm), PDI (0.607), ZP (- 18.41 ± 3.14 mV), %EE (87.9 ± 8.6) and %DL (9.5 ± 1.6).",Sustained release and enhanced oral bioavailability of rivaroxaban by PLGA nanoparticles with no food effect. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31898270/),,87.9,27692,DB06228,Rivaroxaban
,31898270,%DL,"The optimized RXB-PLGA-NPs (F8) with composition, PLGA (125 mg), PVA (0.5%w/w) and RXB (20 mg) was found optimum with particle size (496 ± 8.5 nm), PDI (0.607), ZP (- 18.41 ± 3.14 mV), %EE (87.9 ± 8.6) and %DL (9.5 ± 1.6).",Sustained release and enhanced oral bioavailability of rivaroxaban by PLGA nanoparticles with no food effect. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31898270/),,9.5,27693,DB06228,Rivaroxaban
,22242932,absorption rate,"The estimated absorption rate, apparent clearance and volume of distribution were 1.24 h(-1) (interindividual variability, 139%), 6.48 l h(-1) (31%) and 57.9 l (10%), respectively.",Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242932/),1/[h],1.24,30048,DB06228,Rivaroxaban
,22242932,apparent clearance,"The estimated absorption rate, apparent clearance and volume of distribution were 1.24 h(-1) (interindividual variability, 139%), 6.48 l h(-1) (31%) and 57.9 l (10%), respectively.",Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242932/),[l] / [h],6.48,30049,DB06228,Rivaroxaban
,22242932,volume of distribution,"The estimated absorption rate, apparent clearance and volume of distribution were 1.24 h(-1) (interindividual variability, 139%), 6.48 l h(-1) (31%) and 57.9 l (10%), respectively.",Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242932/),l,57.9,30050,DB06228,Rivaroxaban
,29475063,inhibitory constant (Ki),"DJT06001 inhibited free FXa with an inhibitory constant (Ki) of 0.99 nM, and exhibited >10000-fold selectivity for FXa than for other related serine proteases.","Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29475063/),nM,0.99,35549,DB06228,Rivaroxaban
,29475063,IC50,DJT06001 concentration-dependently inhibited FXa activity in the prothrombinase complex with an IC50 of 2.53 nM.,"Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29475063/),nM,2.53,35550,DB06228,Rivaroxaban
>,20139357,half-maximal inhibitory concentration [IC(50)],"It is selective for human factor Xa, for which it has >10 000-fold greater selectivity than for other biologically relevant serine proteases (half-maximal inhibitory concentration [IC(50)], >20 micromol/L).",Rivaroxaban: a new oral factor Xa inhibitor. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20139357/),[μM] / [l],20,40475,DB06228,Rivaroxaban
,20139357,inhibitory constant [K(i)],"Rivaroxaban inhibits factor Xa in a concentration-dependent manner (inhibitory constant [K(i)], 0.4 nmol/L) and binds rapidly (kinetic association rate constant [k(on)], 1.7x10(7) mol/L(-1) s(-1)) and reversibly (kinetic dissociation rate constant [k(off)], 5x10(-3) s(-1)).",Rivaroxaban: a new oral factor Xa inhibitor. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20139357/),[nM] / [l],0.4,40476,DB06228,Rivaroxaban
,20139357,kinetic association rate constant [k(on)],"Rivaroxaban inhibits factor Xa in a concentration-dependent manner (inhibitory constant [K(i)], 0.4 nmol/L) and binds rapidly (kinetic association rate constant [k(on)], 1.7x10(7) mol/L(-1) s(-1)) and reversibly (kinetic dissociation rate constant [k(off)], 5x10(-3) s(-1)).",Rivaroxaban: a new oral factor Xa inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20139357/),[mol] / [l·s],1.7x10(7),40477,DB06228,Rivaroxaban
,20139357,kinetic dissociation rate constant [k(off)],"Rivaroxaban inhibits factor Xa in a concentration-dependent manner (inhibitory constant [K(i)], 0.4 nmol/L) and binds rapidly (kinetic association rate constant [k(on)], 1.7x10(7) mol/L(-1) s(-1)) and reversibly (kinetic dissociation rate constant [k(off)], 5x10(-3) s(-1)).",Rivaroxaban: a new oral factor Xa inhibitor. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20139357/),1/[s],5x10(-3),40478,DB06228,Rivaroxaban
,20139357,IC(50),"By inhibiting prothrombinase complex-bound (IC(50), 2.1 nmol/L) and clot-associated factor Xa (IC(50), 75 nmol/L), rivaroxaban reduces the thrombin burst during the propagation phase.",Rivaroxaban: a new oral factor Xa inhibitor. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20139357/),[nM] / [l],2.1,40479,DB06228,Rivaroxaban
,20139357,IC(50),"By inhibiting prothrombinase complex-bound (IC(50), 2.1 nmol/L) and clot-associated factor Xa (IC(50), 75 nmol/L), rivaroxaban reduces the thrombin burst during the propagation phase.",Rivaroxaban: a new oral factor Xa inhibitor. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20139357/),[nM] / [l],75,40480,DB06228,Rivaroxaban
,21848931,half-life,"Clinical studies have demonstrated predictable anticoagulation and confirmed dose-proportional effects for rivaroxaban in humans with a rapid onset (within 2-4 h) and a half-life of 7-11 h and 11-13 h for young and elderly subjects, respectively.",Pharmacodynamic and pharmacokinetic basics of rivaroxaban. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21848931/),h,7-11,41757,DB06228,Rivaroxaban
,21848931,half-life,"Clinical studies have demonstrated predictable anticoagulation and confirmed dose-proportional effects for rivaroxaban in humans with a rapid onset (within 2-4 h) and a half-life of 7-11 h and 11-13 h for young and elderly subjects, respectively.",Pharmacodynamic and pharmacokinetic basics of rivaroxaban. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21848931/),h,11-13,41758,DB06228,Rivaroxaban
,21848931,oral bioavailability,"For a 10 mg dose, the oral bioavailability of rivaroxaban is high (80-100%) and is not affected by food intake.",Pharmacodynamic and pharmacokinetic basics of rivaroxaban. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21848931/),%,80-100,41759,DB06228,Rivaroxaban
,18715524,maximum inhibition,"Rivaroxaban pharmacodynamic effects (inhibition of FXa activity and prolongation of prothrombin time, activated partial thromboplastin time and HepTest) all showed a similar pattern, with maximum inhibition of FXa activity increasing from 68% after rivaroxaban 30 mg to 75% after 40 mg and no further increase with the 50 mg dose.",Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18715524/),%,68,42327,DB06228,Rivaroxaban
,18715524,maximum inhibition,"Rivaroxaban pharmacodynamic effects (inhibition of FXa activity and prolongation of prothrombin time, activated partial thromboplastin time and HepTest) all showed a similar pattern, with maximum inhibition of FXa activity increasing from 68% after rivaroxaban 30 mg to 75% after 40 mg and no further increase with the 50 mg dose.",Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18715524/),%,75,42328,DB06228,Rivaroxaban
,17334516,ED(50),"In the prevention model, rivaroxaban reduced thrombus formation dose-dependently (calculated ED(50) 1.3 mg/kg).","Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17334516/),[mg] / [kg],1.3,50323,DB06228,Rivaroxaban
,29977164,terminal half-life,"Betrixaban has the longest half-life among the DOAC class, with a terminal half-life of 35-45 h and an effective half-life of 19-27 h.",Pharmacological properties of betrixaban. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29977164/),h,35-45,53299,DB06228,Rivaroxaban
,29977164,effective half-life,"Betrixaban has the longest half-life among the DOAC class, with a terminal half-life of 35-45 h and an effective half-life of 19-27 h.",Pharmacological properties of betrixaban. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29977164/),h,19-27,53300,DB06228,Rivaroxaban
,26597179,peak effect,"The peak effect of edoxaban on prothrombin time (PT) after 4 days of edoxaban only was 21.8 ± 2.46 s; after switching from rivaroxaban to edoxaban, peak effect on PT was similar at 21.8 ± 2.88 s.",Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26597179/),s,21.8,56984,DB06228,Rivaroxaban
,26597179,peak effect,"The peak effect of edoxaban on prothrombin time (PT) after 4 days of edoxaban only was 21.8 ± 2.46 s; after switching from rivaroxaban to edoxaban, peak effect on PT was similar at 21.8 ± 2.88 s.",Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26597179/),s,21.8,56985,DB06228,Rivaroxaban
,26597179,least,"After switching from dabigatran etexilate to edoxaban, least squares mean activated partial thromboplastin time (aPTT) at 2 h after administration was 47.6 vs 35.0 s for edoxaban alone.",Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26597179/),s,47.6,56986,DB06228,Rivaroxaban
,26597179,activated partial thromboplastin time (aPTT),"After switching from dabigatran etexilate to edoxaban, least squares mean activated partial thromboplastin time (aPTT) at 2 h after administration was 47.6 vs 35.0 s for edoxaban alone.",Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26597179/),s,47.6,56987,DB06228,Rivaroxaban
,26597179,activated partial thromboplastin time (aPTT),"After switching from dabigatran etexilate to edoxaban, least squares mean activated partial thromboplastin time (aPTT) at 2 h after administration was 47.6 vs 35.0 s for edoxaban alone.",Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26597179/),s,35.0,56988,DB06228,Rivaroxaban
exceeded,29055248,Extraction recoveries,Extraction recoveries exceeded 80 %.,Simultaneous quantification of direct oral anticoagulants currently used in anticoagulation therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29055248/),%,80,60787,DB06228,Rivaroxaban
,23999929,Oral bioavailability,Oral bioavailability is high (80-100 %) for the 10 mg tablet irrespective of food intake and for the 15 mg and 20 mg tablets when taken with food.,Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23999929/),%,80-100,71673,DB06228,Rivaroxaban
,23999929,terminal half-life,Elimination of rivaroxaban from plasma occurs with a terminal half-life of 5-9 h in healthy young subjects and 11-13 h in elderly subjects.,Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23999929/),h,5-9,71674,DB06228,Rivaroxaban
,23999929,terminal half-life,Elimination of rivaroxaban from plasma occurs with a terminal half-life of 5-9 h in healthy young subjects and 11-13 h in elderly subjects.,Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23999929/),h,11-13,71675,DB06228,Rivaroxaban
,19066002,bioavailability,"After oral administration the absorption is near 100%, the bioavailability is near 80%, and the elimination half-life is 5-9 hours with mixed excretion via the renal and fecal/biliary routes.",New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19066002/),%,80,88857,DB06228,Rivaroxaban
,19066002,elimination half-life,"After oral administration the absorption is near 100%, the bioavailability is near 80%, and the elimination half-life is 5-9 hours with mixed excretion via the renal and fecal/biliary routes.",New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19066002/),h,5-9,88858,DB06228,Rivaroxaban
,31931327,MRM transitions,"The MRM transitions were set to 441.14 > 379.09 and 436.89 > 144.87 for delafloxacin and internal standard, respectively.",Development and validation of a novel UPLC-MS/MS method for quantification of delafloxacin in plasma and aqueous humour for pharmacokinetic analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31931327/),,441.14,88925,DB06228,Rivaroxaban
,31931327,MRM transitions,"The MRM transitions were set to 441.14 > 379.09 and 436.89 > 144.87 for delafloxacin and internal standard, respectively.",Development and validation of a novel UPLC-MS/MS method for quantification of delafloxacin in plasma and aqueous humour for pharmacokinetic analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31931327/),,379.09,88926,DB06228,Rivaroxaban
,31931327,MRM transitions,"The MRM transitions were set to 441.14 > 379.09 and 436.89 > 144.87 for delafloxacin and internal standard, respectively.",Development and validation of a novel UPLC-MS/MS method for quantification of delafloxacin in plasma and aqueous humour for pharmacokinetic analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31931327/),,436.89,88927,DB06228,Rivaroxaban
,31931327,MRM transitions,"The MRM transitions were set to 441.14 > 379.09 and 436.89 > 144.87 for delafloxacin and internal standard, respectively.",Development and validation of a novel UPLC-MS/MS method for quantification of delafloxacin in plasma and aqueous humour for pharmacokinetic analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31931327/),,144.87,88928,DB06228,Rivaroxaban
,31682296,RBC loss,"Among patients undergoing surgery with low expected blood loss, RBC loss varied from 164 mL (standard deviation [SD], 189) to 302 mL (SD, 397) (p = 0.66), and no association of calculated RXA concentration with RBC loss was observed.",Impact of rivaroxaban plasma concentration on perioperative red blood cell loss. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31682296/),ml,164,91913,DB06228,Rivaroxaban
,31682296,RBC loss,"Among patients undergoing surgery with low expected blood loss, RBC loss varied from 164 mL (standard deviation [SD], 189) to 302 mL (SD, 397) (p = 0.66), and no association of calculated RXA concentration with RBC loss was observed.",Impact of rivaroxaban plasma concentration on perioperative red blood cell loss. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31682296/),ml,302,91914,DB06228,Rivaroxaban
,25419161,time-to-maximum concentration,"Median time-to-maximum concentration was 2 hours for both compounds, and the mean half-life was 8.7 and 7.9 hours for apixaban and rivaroxaban, respectively.",A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25419161/),h,2,94072,DB06228,Rivaroxaban
,25419161,half-life,"Median time-to-maximum concentration was 2 hours for both compounds, and the mean half-life was 8.7 and 7.9 hours for apixaban and rivaroxaban, respectively.",A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25419161/),h,8.7,94073,DB06228,Rivaroxaban
,25419161,half-life,"Median time-to-maximum concentration was 2 hours for both compounds, and the mean half-life was 8.7 and 7.9 hours for apixaban and rivaroxaban, respectively.",A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25419161/),h,7.9,94074,DB06228,Rivaroxaban
,25419161,area under the curve (AUC(0-24)),"Daily exposure, the area under the curve (AUC(0-24)), appeared similar for rivaroxaban (1,094 ng · h/mL) and apixaban (935 ng · h/mL), whereas mean peak-to-trough plasma concentration ratio was 3.6-fold greater for rivaroxaban (16.9) than apixaban (4.7).",A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25419161/),[h·ng] / [ml],"1,094",94075,DB06228,Rivaroxaban
,25419161,area under the curve (AUC(0-24)),"Daily exposure, the area under the curve (AUC(0-24)), appeared similar for rivaroxaban (1,094 ng · h/mL) and apixaban (935 ng · h/mL), whereas mean peak-to-trough plasma concentration ratio was 3.6-fold greater for rivaroxaban (16.9) than apixaban (4.7).",A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25419161/),[h·ng] / [ml],935,94076,DB06228,Rivaroxaban
,25419161,peak-to-trough plasma concentration ratio,"Daily exposure, the area under the curve (AUC(0-24)), appeared similar for rivaroxaban (1,094 ng · h/mL) and apixaban (935 ng · h/mL), whereas mean peak-to-trough plasma concentration ratio was 3.6-fold greater for rivaroxaban (16.9) than apixaban (4.7).",A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25419161/),,16.9,94077,DB06228,Rivaroxaban
,25419161,peak-to-trough plasma concentration ratio,"Daily exposure, the area under the curve (AUC(0-24)), appeared similar for rivaroxaban (1,094 ng · h/mL) and apixaban (935 ng · h/mL), whereas mean peak-to-trough plasma concentration ratio was 3.6-fold greater for rivaroxaban (16.9) than apixaban (4.7).",A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25419161/),,4.7,94078,DB06228,Rivaroxaban
,25419161,Trough concentrations,"Trough concentrations and AXA were lower for rivaroxaban (10 ng/mL and 0.17 IU/mL vs 17 ng/mL and 0.24 IU/mL for apixaban, respectively).",A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25419161/),[ng] / [ml],10,94079,DB06228,Rivaroxaban
,25419161,Trough concentrations,"Trough concentrations and AXA were lower for rivaroxaban (10 ng/mL and 0.17 IU/mL vs 17 ng/mL and 0.24 IU/mL for apixaban, respectively).",A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25419161/),[iu] / [ml],0.17,94080,DB06228,Rivaroxaban
,25419161,Trough concentrations,"Trough concentrations and AXA were lower for rivaroxaban (10 ng/mL and 0.17 IU/mL vs 17 ng/mL and 0.24 IU/mL for apixaban, respectively).",A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25419161/),[ng] / [ml],17,94081,DB06228,Rivaroxaban
,25419161,AXA,"Trough concentrations and AXA were lower for rivaroxaban (10 ng/mL and 0.17 IU/mL vs 17 ng/mL and 0.24 IU/mL for apixaban, respectively).",A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25419161/),[iu] / [ml],0.17,94082,DB06228,Rivaroxaban
,25419161,AXA,"Trough concentrations and AXA were lower for rivaroxaban (10 ng/mL and 0.17 IU/mL vs 17 ng/mL and 0.24 IU/mL for apixaban, respectively).",A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25419161/),[iu] / [ml],0.24,94083,DB06228,Rivaroxaban
,33107158,oral bioavailability,"Rivaroxaban is a new anticoagulant option for dogs, yet its reported oral bioavailability is as low as 60%.",The influence of feeding and gastroprotectant medications on the Factor Xa inhibitory activity of orally administered rivaroxaban in normal dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33107158/),%,60,95797,DB06228,Rivaroxaban
,33885176,linear concentration,The linear concentration range was 1-600 ng/mL.,Sensitive LC-MS/MS method for quantification of rivaroxaban in plasma: Application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33885176/),[ng] / [ml],1-600,97266,DB06228,Rivaroxaban
≥,23458226,oral bioavailability,"Independent of food and formulation, pharmacokinetic parameters of doses up to 10 mg rivaroxaban were dose proportional and had high oral bioavailability (≥ 80%).",The effect of food on the absorption and pharmacokinetics of rivaroxaban. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458226/),%,80,97524,DB06228,Rivaroxaban
≥,23458226,bioavailability,"However, when taken with food, high bioavailability (≥ 80%) of these doses was achieved independent of formulation.",The effect of food on the absorption and pharmacokinetics of rivaroxaban. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458226/),%,80,97525,DB06228,Rivaroxaban
≥,23458226,bioavailability,"High bioavailability (≥ 80%) of 15 mg and 20 mg rivaroxaban was achieved when taken with food; therefore, these doses need to be taken with food.",The effect of food on the absorption and pharmacokinetics of rivaroxaban. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458226/),%,80,97526,DB06228,Rivaroxaban
,27116356,flow rate,"The analytes and the internal standard (diazepam) were separated on an Acquity UPLC BEH C18 chromatography column (2.1 mm × 50 mm, 1.7 μm) using gradient elution with a mobile phase of acetonitrile and 0.1 % formic acid in water at a flow rate of 0.4 mL/min.","Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27116356/),[ml] / [min],0.4,100915,DB06228,Rivaroxaban
,27116356,m/,"The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring mode to monitor the precursor-to-product ion transitions of m/z 436.1 → 145.1 for rivaroxaban, m/z 460.0 → 443.1 for apixaban, m/z 548.2 → 366.1 for edoxaban and m/z 285.2 → 193.1 for diazepam (IS) using a positive electrospray ionization interface.","Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27116356/),,460.0,100916,DB06228,Rivaroxaban
,27116356,m/z,"The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring mode to monitor the precursor-to-product ion transitions of m/z 436.1 → 145.1 for rivaroxaban, m/z 460.0 → 443.1 for apixaban, m/z 548.2 → 366.1 for edoxaban and m/z 285.2 → 193.1 for diazepam (IS) using a positive electrospray ionization interface.","Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27116356/),,548.2,100917,DB06228,Rivaroxaban
,27116356,m/z,"The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring mode to monitor the precursor-to-product ion transitions of m/z 436.1 → 145.1 for rivaroxaban, m/z 460.0 → 443.1 for apixaban, m/z 548.2 → 366.1 for edoxaban and m/z 285.2 → 193.1 for diazepam (IS) using a positive electrospray ionization interface.","Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27116356/),,366.1,100918,DB06228,Rivaroxaban
,27116356,m/z,"The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring mode to monitor the precursor-to-product ion transitions of m/z 436.1 → 145.1 for rivaroxaban, m/z 460.0 → 443.1 for apixaban, m/z 548.2 → 366.1 for edoxaban and m/z 285.2 → 193.1 for diazepam (IS) using a positive electrospray ionization interface.","Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27116356/),,285.2,100919,DB06228,Rivaroxaban
,27116356,m/z,"The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring mode to monitor the precursor-to-product ion transitions of m/z 436.1 → 145.1 for rivaroxaban, m/z 460.0 → 443.1 for apixaban, m/z 548.2 → 366.1 for edoxaban and m/z 285.2 → 193.1 for diazepam (IS) using a positive electrospray ionization interface.","Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27116356/),,193.1,100920,DB06228,Rivaroxaban
,27116356,Total time,Total time for each chromatograph was 3.5 min.,"Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27116356/),min,3.5,100921,DB06228,Rivaroxaban
,16328318,terminal half-life,The terminal half-life of BAY 59-7939 was 5.7-9.2 h at steady state.,"Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16328318/),h,5.7-9.2,105286,DB06228,Rivaroxaban
,25280819,prothrombin time (PT),"Clinical data on admission were as follows: blood pressure, 170/90 mm Hg; prothrombin time (PT), 22.6 seconds (control, 12.9 seconds); international normalized ratio, 2.03; activated partial thromboplastin time, 46 seconds (normal, 23-32 seconds); and creatinine level, 1.11 mg/dL.",Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with rivaroxaban. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25280819/),seconds,22.6,111299,DB06228,Rivaroxaban
,25280819,prothrombin time (PT),"Clinical data on admission were as follows: blood pressure, 170/90 mm Hg; prothrombin time (PT), 22.6 seconds (control, 12.9 seconds); international normalized ratio, 2.03; activated partial thromboplastin time, 46 seconds (normal, 23-32 seconds); and creatinine level, 1.11 mg/dL.",Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with rivaroxaban. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25280819/),seconds,12.9,111300,DB06228,Rivaroxaban
,25280819,international normalized ratio,"Clinical data on admission were as follows: blood pressure, 170/90 mm Hg; prothrombin time (PT), 22.6 seconds (control, 12.9 seconds); international normalized ratio, 2.03; activated partial thromboplastin time, 46 seconds (normal, 23-32 seconds); and creatinine level, 1.11 mg/dL.",Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with rivaroxaban. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25280819/),,2.03,111301,DB06228,Rivaroxaban
,25280819,activated partial thromboplastin time,"Clinical data on admission were as follows: blood pressure, 170/90 mm Hg; prothrombin time (PT), 22.6 seconds (control, 12.9 seconds); international normalized ratio, 2.03; activated partial thromboplastin time, 46 seconds (normal, 23-32 seconds); and creatinine level, 1.11 mg/dL.",Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with rivaroxaban. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25280819/),seconds,46,111302,DB06228,Rivaroxaban
,16308283,absolute bioavailability,"BAY 59-7939 was rapidly absorbed after oral dosing, with an absolute bioavailability of 57-66% in rats, and 60-86% in dogs.","Pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--in rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16308283/),%,57-66,122896,DB06228,Rivaroxaban
,16308283,absolute bioavailability,"BAY 59-7939 was rapidly absorbed after oral dosing, with an absolute bioavailability of 57-66% in rats, and 60-86% in dogs.","Pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--in rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16308283/),%,60-86,122897,DB06228,Rivaroxaban
,16308283,Plasma clearance,"Plasma clearance was low: 0.4 l kg(-1) h(-1) in rats and 0.3 l kg(-1) h(-1) in dogs; volume of distribution (V(ss)) was moderate: 0.3 l kg(-1) in rats, and 0.4 l kg(-1) in dogs.","Pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16308283/),[l] / [h·kg],0.4,122898,DB06228,Rivaroxaban
,16308283,Plasma clearance,"Plasma clearance was low: 0.4 l kg(-1) h(-1) in rats and 0.3 l kg(-1) h(-1) in dogs; volume of distribution (V(ss)) was moderate: 0.3 l kg(-1) in rats, and 0.4 l kg(-1) in dogs.","Pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16308283/),[l] / [h·kg],0.3,122899,DB06228,Rivaroxaban
,16308283,volume of distribution (V(ss)),"Plasma clearance was low: 0.4 l kg(-1) h(-1) in rats and 0.3 l kg(-1) h(-1) in dogs; volume of distribution (V(ss)) was moderate: 0.3 l kg(-1) in rats, and 0.4 l kg(-1) in dogs.","Pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--in rats and dogs. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16308283/),[l] / [kg],0.3,122900,DB06228,Rivaroxaban
,16308283,volume of distribution (V(ss)),"Plasma clearance was low: 0.4 l kg(-1) h(-1) in rats and 0.3 l kg(-1) h(-1) in dogs; volume of distribution (V(ss)) was moderate: 0.3 l kg(-1) in rats, and 0.4 l kg(-1) in dogs.","Pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--in rats and dogs. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16308283/),[l] / [kg],0.4,122901,DB06228,Rivaroxaban
,16308283,elimination half-life,The elimination half-life after oral administration was short in both species (0.9-2.3 h).,"Pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--in rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16308283/),h,0.9-2.3,122902,DB06228,Rivaroxaban
,27893182,AUC ratios,"ABCB1 genotype did not significantly affect drug pharmacokinetics: AUC ratios between mutant-allele carriers and wild-type volunteers were 1.27 (95% confidence interval [CI] 0.84-1.92) and 1.20 (95% CI 0.96-1.51) for dabigatran and rivaroxaban, respectively.",Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27893182/),,1.27,124437,DB06228,Rivaroxaban
,27893182,AUC ratios,"ABCB1 genotype did not significantly affect drug pharmacokinetics: AUC ratios between mutant-allele carriers and wild-type volunteers were 1.27 (95% confidence interval [CI] 0.84-1.92) and 1.20 (95% CI 0.96-1.51) for dabigatran and rivaroxaban, respectively.",Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27893182/),,1.20,124438,DB06228,Rivaroxaban
,29127863,Ctrough,"After 5days of dabigatran dosing, Ctrough and Cmax geometric means were 39μg/L (90% CI: 23-66) and 88μg/L (90% CI: 56-137), respectively; AUC0-12h was 958μg∗h/L (90% CI: 635-1445).",Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29127863/),[μg] / [l],39,126748,DB06228,Rivaroxaban
,29127863,Cmax,"After 5days of dabigatran dosing, Ctrough and Cmax geometric means were 39μg/L (90% CI: 23-66) and 88μg/L (90% CI: 56-137), respectively; AUC0-12h was 958μg∗h/L (90% CI: 635-1445).",Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29127863/),[μg] / [l],88,126749,DB06228,Rivaroxaban
,29127863,AUC0-12h,"After 5days of dabigatran dosing, Ctrough and Cmax geometric means were 39μg/L (90% CI: 23-66) and 88μg/L (90% CI: 56-137), respectively; AUC0-12h was 958μg∗h/L (90% CI: 635-1445).",Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29127863/),[μg∗h] / [l],958,126750,DB06228,Rivaroxaban
,29127863,Ctrough,"After 5days of rivaroxaban dosing, Ctrough and Cmax geometric means were 9μg/L (90% CI: 1-71) and 167μg/L (90% CI: 102-276), respectively; AUC0-24h was 1720μg∗h/L (90% CI: 899-3300).",Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29127863/),[μg] / [l],9,126751,DB06228,Rivaroxaban
,29127863,Cmax,"After 5days of rivaroxaban dosing, Ctrough and Cmax geometric means were 9μg/L (90% CI: 1-71) and 167μg/L (90% CI: 102-276), respectively; AUC0-24h was 1720μg∗h/L (90% CI: 899-3300).",Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29127863/),[μg] / [l],167,126752,DB06228,Rivaroxaban
,29127863,AUC0-24h,"After 5days of rivaroxaban dosing, Ctrough and Cmax geometric means were 9μg/L (90% CI: 1-71) and 167μg/L (90% CI: 102-276), respectively; AUC0-24h was 1720μg∗h/L (90% CI: 899-3300).",Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29127863/),[μg∗h] / [l],1720,126753,DB06228,Rivaroxaban
,29127863,Cmax ratio,"For dabigatran, Cmax ratio was 0.57 (SD 0.33) and Ctrough ratio was 0.35 (SD 0.44).",Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29127863/),,0.57,126754,DB06228,Rivaroxaban
,29127863,Ctrough ratio,"For dabigatran, Cmax ratio was 0.57 (SD 0.33) and Ctrough ratio was 0.35 (SD 0.44).",Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29127863/),,0.35,126755,DB06228,Rivaroxaban
,19185782,bioavailability,"The main pharmacokinetic characteristics of rivaroxaban are a bioavailability of approximately 80-100%, a maximum concentration obtained in 2 to 4 hours, a terminal half-life of elimination of 7 to 11 hours, a renal elimination for 1/3 for the active hepatic metabolism from the cytochrome P450 (3A4) for the other 2/3.",[Rivaroxaban: clinical pharmacology]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19185782/),%,80-100,130634,DB06228,Rivaroxaban
,19185782,terminal half-life of elimination,"The main pharmacokinetic characteristics of rivaroxaban are a bioavailability of approximately 80-100%, a maximum concentration obtained in 2 to 4 hours, a terminal half-life of elimination of 7 to 11 hours, a renal elimination for 1/3 for the active hepatic metabolism from the cytochrome P450 (3A4) for the other 2/3.",[Rivaroxaban: clinical pharmacology]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19185782/),h,7 to 11,130635,DB06228,Rivaroxaban
,23466964,IC2x LT,"Their inhibitory potencies, expressed as IC2x LT, IC2x TTP, IC50 ETP, IC50 peak thrombin, and IC50 Vmax, were as follows: 0.10 ± 0.01, 0.19 ± 0.02, 0.65 ± 0.11, 0.089 ± 0.019, and 0.049 ± 0.007 μM for apixaban; 0.049 ± 0.007, 0.070 ± 0.009, 0.43 ± 0.07, 0.048 ± 0.008, and 0.022 ± 0.005 μM for rivaroxaban; and 0.063 ± 0.019, 0.18 ± 0.06, 0.50 ± 0.08, 0.55 ± 0.06, and 0.57 ± 0.27 μM for dabigatran.",Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23466964/),μM,0.10,132118,DB06228,Rivaroxaban
,23466964,IC50 Vmax,"Their inhibitory potencies, expressed as IC2x LT, IC2x TTP, IC50 ETP, IC50 peak thrombin, and IC50 Vmax, were as follows: 0.10 ± 0.01, 0.19 ± 0.02, 0.65 ± 0.11, 0.089 ± 0.019, and 0.049 ± 0.007 μM for apixaban; 0.049 ± 0.007, 0.070 ± 0.009, 0.43 ± 0.07, 0.048 ± 0.008, and 0.022 ± 0.005 μM for rivaroxaban; and 0.063 ± 0.019, 0.18 ± 0.06, 0.50 ± 0.08, 0.55 ± 0.06, and 0.57 ± 0.27 μM for dabigatran.",Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23466964/),μM,0.063,132119,DB06228,Rivaroxaban
,23466964,IC50 Vmax,"Their inhibitory potencies, expressed as IC2x LT, IC2x TTP, IC50 ETP, IC50 peak thrombin, and IC50 Vmax, were as follows: 0.10 ± 0.01, 0.19 ± 0.02, 0.65 ± 0.11, 0.089 ± 0.019, and 0.049 ± 0.007 μM for apixaban; 0.049 ± 0.007, 0.070 ± 0.009, 0.43 ± 0.07, 0.048 ± 0.008, and 0.022 ± 0.005 μM for rivaroxaban; and 0.063 ± 0.019, 0.18 ± 0.06, 0.50 ± 0.08, 0.55 ± 0.06, and 0.57 ± 0.27 μM for dabigatran.",Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23466964/),μM,0.18,132120,DB06228,Rivaroxaban
,23466964,IC50 Vmax,"Their inhibitory potencies, expressed as IC2x LT, IC2x TTP, IC50 ETP, IC50 peak thrombin, and IC50 Vmax, were as follows: 0.10 ± 0.01, 0.19 ± 0.02, 0.65 ± 0.11, 0.089 ± 0.019, and 0.049 ± 0.007 μM for apixaban; 0.049 ± 0.007, 0.070 ± 0.009, 0.43 ± 0.07, 0.048 ± 0.008, and 0.022 ± 0.005 μM for rivaroxaban; and 0.063 ± 0.019, 0.18 ± 0.06, 0.50 ± 0.08, 0.55 ± 0.06, and 0.57 ± 0.27 μM for dabigatran.",Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23466964/),μM,0.50,132121,DB06228,Rivaroxaban
,23466964,IC50 Vmax,"Their inhibitory potencies, expressed as IC2x LT, IC2x TTP, IC50 ETP, IC50 peak thrombin, and IC50 Vmax, were as follows: 0.10 ± 0.01, 0.19 ± 0.02, 0.65 ± 0.11, 0.089 ± 0.019, and 0.049 ± 0.007 μM for apixaban; 0.049 ± 0.007, 0.070 ± 0.009, 0.43 ± 0.07, 0.048 ± 0.008, and 0.022 ± 0.005 μM for rivaroxaban; and 0.063 ± 0.019, 0.18 ± 0.06, 0.50 ± 0.08, 0.55 ± 0.06, and 0.57 ± 0.27 μM for dabigatran.",Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23466964/),μM,0.55,132122,DB06228,Rivaroxaban
,34155947,trough,"The median doseadjusted tacrolimus trough and tacrolimus total daily dose prior to rivaroxaban/apixaban initiation was 2.15 ng/mL/mg (IQR 1.17, 3.37) and 4 mg (IQR 1.88, 6.25), respectively.",The Impact of Rivaroxaban and Apixaban on Tacrolimus Trough Levels. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34155947/),[ng] / [mg·ml],2.15,133517,DB06228,Rivaroxaban
,34155947,total daily dose,"The median doseadjusted tacrolimus trough and tacrolimus total daily dose prior to rivaroxaban/apixaban initiation was 2.15 ng/mL/mg (IQR 1.17, 3.37) and 4 mg (IQR 1.88, 6.25), respectively.",The Impact of Rivaroxaban and Apixaban on Tacrolimus Trough Levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34155947/),mg,4,133518,DB06228,Rivaroxaban
,34155947,trough,"The median dose-adjusted tacrolimus trough and tacrolimus total daily dose after rivaroxaban/apixaban initiation was 2.16 ng/mL/mg (IQR 1.24, 4.10) and 3.55 mg (IQR 1.5, 6.35), respectively.",The Impact of Rivaroxaban and Apixaban on Tacrolimus Trough Levels. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34155947/),[ng] / [mg·ml],2.16,133519,DB06228,Rivaroxaban
,34155947,total daily dose,"The median dose-adjusted tacrolimus trough and tacrolimus total daily dose after rivaroxaban/apixaban initiation was 2.16 ng/mL/mg (IQR 1.24, 4.10) and 3.55 mg (IQR 1.5, 6.35), respectively.",The Impact of Rivaroxaban and Apixaban on Tacrolimus Trough Levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34155947/),mg,3.55,133520,DB06228,Rivaroxaban
,26842561,steady state peak,"Based on drug concentrations previously published in pharmacokinetic studies, the expected steady state peak and trough antifactor Xa activity ranges for apixaban are 1.80 to 2.20 IU/mL and 0.70 to 1.10 IU/mL, respectively.",Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26842561/),[iu] / [ml],1.80 to 2.20,137223,DB06228,Rivaroxaban
,26842561,trough antifactor Xa activity,"Based on drug concentrations previously published in pharmacokinetic studies, the expected steady state peak and trough antifactor Xa activity ranges for apixaban are 1.80 to 2.20 IU/mL and 0.70 to 1.10 IU/mL, respectively.",Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26842561/),[iu] / [ml],0.70 to 1.10,137224,DB06228,Rivaroxaban
,25804678,AUC0-44,"Mean AUC0-44 of rivaroxaban plasma concentrations after a single dose of 10mg was 2,072μg/L/h, mean maximum concentration was 172.6μg/L, and mean terminal elimination half-life was 8.6 hours.",Dose-finding study of rivaroxaban in hemodialysis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25804678/),[μg] / [h·l],"2,072",144781,DB06228,Rivaroxaban
,25804678,maximum concentration,"Mean AUC0-44 of rivaroxaban plasma concentrations after a single dose of 10mg was 2,072μg/L/h, mean maximum concentration was 172.6μg/L, and mean terminal elimination half-life was 8.6 hours.",Dose-finding study of rivaroxaban in hemodialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25804678/),[μg] / [l],172.6,144782,DB06228,Rivaroxaban
,25804678,terminal elimination half-life,"Mean AUC0-44 of rivaroxaban plasma concentrations after a single dose of 10mg was 2,072μg/L/h, mean maximum concentration was 172.6μg/L, and mean terminal elimination half-life was 8.6 hours.",Dose-finding study of rivaroxaban in hemodialysis patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25804678/),h,8.6,144783,DB06228,Rivaroxaban
,25804678,trough concentration,Mean trough concentration after multiple daily doses of 10mg was 20.2μg/L.,Dose-finding study of rivaroxaban in hemodialysis patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25804678/),[μg] / [l],20.2,144784,DB06228,Rivaroxaban
,27128839,recovery,There were no significant changes in mean percent of non-degraded rivaroxaban recovered over 4 hours from crushed tablet suspensions (>98.4% recovery across all suspensions and time points) or after NG tube exposure (recovery: 99.1% for silicone and 98.9% for polyvinyl chloride NG tubes).,Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128839/),%,99.1,148021,DB06228,Rivaroxaban
,27128839,recovery,There were no significant changes in mean percent of non-degraded rivaroxaban recovered over 4 hours from crushed tablet suspensions (>98.4% recovery across all suspensions and time points) or after NG tube exposure (recovery: 99.1% for silicone and 98.9% for polyvinyl chloride NG tubes).,Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128839/),%,98.9,148022,DB06228,Rivaroxaban
,22177763,half-life,"The half-life is around 8 to 12 hours, with a peak activity 2 to 4 hours after ingestion.",[Pharmacologic heterogeneity of new anticoagulants]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22177763/),h,8 to 12,148054,DB06228,Rivaroxaban
,25475601,maximum effect (Emax ),"The mean maximum effect (Emax ) for INR after co-administration was 2.79-4.15 (mean PT Emax 41.0-62.7 s), compared with 1.41-1.74 (mean PT Emax 20.1-25.2 s) for warfarin alone.",Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25475601/),,2.79-4.15,156004,DB06228,Rivaroxaban
,25475601,Emax,"The mean maximum effect (Emax ) for INR after co-administration was 2.79-4.15 (mean PT Emax 41.0-62.7 s), compared with 1.41-1.74 (mean PT Emax 20.1-25.2 s) for warfarin alone.",Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25475601/),s,41.0-62.7,156005,DB06228,Rivaroxaban
,25475601,Emax,"The mean maximum effect (Emax ) for INR after co-administration was 2.79-4.15 (mean PT Emax 41.0-62.7 s), compared with 1.41-1.74 (mean PT Emax 20.1-25.2 s) for warfarin alone.",Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25475601/),,1.41-1.74,156006,DB06228,Rivaroxaban
,25475601,Emax,"The mean maximum effect (Emax ) for INR after co-administration was 2.79-4.15 (mean PT Emax 41.0-62.7 s), compared with 1.41-1.74 (mean PT Emax 20.1-25.2 s) for warfarin alone.",Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25475601/),s,20.1-25.2,156007,DB06228,Rivaroxaban
,32466800,steady state concentration,"The range of the steady state concentration in patients that took 15 mg rivaroxaban twice daily, 10 mg twice daily, 20 mg once daily, 15 mg once daily, and 10 mg once daily were 168.5 ~ 280.1 ng•mL- 1, 74.2 ~ 271.4 ng•mL- 1, 25.7 ~ 306.8 ng•mL- 1, 24.5 ~ 306.4 ng•mL- 1, and 15.4 ~ 229.2 ng•mL- 1, respectively.",Laboratory monitoring of rivaroxaban in Chinese patients with deep venous thrombosis: a preliminary study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32466800/),1·ml-·ng,168,156554,DB06228,Rivaroxaban
,32466800,steady state concentration,"The range of the steady state concentration in patients that took 15 mg rivaroxaban twice daily, 10 mg twice daily, 20 mg once daily, 15 mg once daily, and 10 mg once daily were 168.5 ~ 280.1 ng•mL- 1, 74.2 ~ 271.4 ng•mL- 1, 25.7 ~ 306.8 ng•mL- 1, 24.5 ~ 306.4 ng•mL- 1, and 15.4 ~ 229.2 ng•mL- 1, respectively.",Laboratory monitoring of rivaroxaban in Chinese patients with deep venous thrombosis: a preliminary study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32466800/),1·ml-·ng,74,156555,DB06228,Rivaroxaban
,32466800,steady state concentration,"The range of the steady state concentration in patients that took 15 mg rivaroxaban twice daily, 10 mg twice daily, 20 mg once daily, 15 mg once daily, and 10 mg once daily were 168.5 ~ 280.1 ng•mL- 1, 74.2 ~ 271.4 ng•mL- 1, 25.7 ~ 306.8 ng•mL- 1, 24.5 ~ 306.4 ng•mL- 1, and 15.4 ~ 229.2 ng•mL- 1, respectively.",Laboratory monitoring of rivaroxaban in Chinese patients with deep venous thrombosis: a preliminary study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32466800/),1·ml-·ng,25.7 ~ 306.8,156556,DB06228,Rivaroxaban
,32466800,steady state concentration,"The range of the steady state concentration in patients that took 15 mg rivaroxaban twice daily, 10 mg twice daily, 20 mg once daily, 15 mg once daily, and 10 mg once daily were 168.5 ~ 280.1 ng•mL- 1, 74.2 ~ 271.4 ng•mL- 1, 25.7 ~ 306.8 ng•mL- 1, 24.5 ~ 306.4 ng•mL- 1, and 15.4 ~ 229.2 ng•mL- 1, respectively.",Laboratory monitoring of rivaroxaban in Chinese patients with deep venous thrombosis: a preliminary study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32466800/),1·ml-·ng,24.5 ~ 306.4,156557,DB06228,Rivaroxaban
,32466800,steady state concentration,"The range of the steady state concentration in patients that took 15 mg rivaroxaban twice daily, 10 mg twice daily, 20 mg once daily, 15 mg once daily, and 10 mg once daily were 168.5 ~ 280.1 ng•mL- 1, 74.2 ~ 271.4 ng•mL- 1, 25.7 ~ 306.8 ng•mL- 1, 24.5 ~ 306.4 ng•mL- 1, and 15.4 ~ 229.2 ng•mL- 1, respectively.",Laboratory monitoring of rivaroxaban in Chinese patients with deep venous thrombosis: a preliminary study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32466800/),1·ml-·ng,15.4 ~ 229.2,156558,DB06228,Rivaroxaban
,32959922,Tmax,"No clinically significant differences were found regarding Tmax (median 1.5 vs 1 h, P = .26) and terminal elimination half-life (mean 10.6 vs 10.8 h, P = .93) of rivaroxaban.",Effects of Hypericum perforatum (St John's wort) on the pharmacokinetics and pharmacodynamics of rivaroxaban in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959922/),h,1.5,158149,DB06228,Rivaroxaban
,32959922,Tmax,"No clinically significant differences were found regarding Tmax (median 1.5 vs 1 h, P = .26) and terminal elimination half-life (mean 10.6 vs 10.8 h, P = .93) of rivaroxaban.",Effects of Hypericum perforatum (St John's wort) on the pharmacokinetics and pharmacodynamics of rivaroxaban in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959922/),h,1,158150,DB06228,Rivaroxaban
,32959922,terminal elimination half-life,"No clinically significant differences were found regarding Tmax (median 1.5 vs 1 h, P = .26) and terminal elimination half-life (mean 10.6 vs 10.8 h, P = .93) of rivaroxaban.",Effects of Hypericum perforatum (St John's wort) on the pharmacokinetics and pharmacodynamics of rivaroxaban in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959922/),h,10.6,158151,DB06228,Rivaroxaban
,32959922,terminal elimination half-life,"No clinically significant differences were found regarding Tmax (median 1.5 vs 1 h, P = .26) and terminal elimination half-life (mean 10.6 vs 10.8 h, P = .93) of rivaroxaban.",Effects of Hypericum perforatum (St John's wort) on the pharmacokinetics and pharmacodynamics of rivaroxaban in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959922/),h,10.8,158152,DB06228,Rivaroxaban
,17595891,apparent oral clearance,"Population mean estimates for apparent oral clearance and volume of distribution for the central compartment were 9.2 1/h and 55 1, respectively, with moderate inter-individual variability (17.4% and 30.7%, respectively).","Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17595891/),[1] / [h],9.2,161761,DB06228,Rivaroxaban
,17595891,volume of distribution for the central compartment,"Population mean estimates for apparent oral clearance and volume of distribution for the central compartment were 9.2 1/h and 55 1, respectively, with moderate inter-individual variability (17.4% and 30.7%, respectively).","Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17595891/),1,55,161762,DB06228,Rivaroxaban
,17595891,Total volume of distribution,Total volume of distribution for rivaroxaban at steady state was approximately 70 1.,"Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17595891/),1,70,161763,DB06228,Rivaroxaban
,29260434,binding constants,A decline in the values of binding constants was detected with the increase of temperatures (298-308 K) and the binding constants were in range from 1.32 × 105 to 4.3 × 103 L mol-1 indicating the instability of the BSA and rivaroxaban complex at higher temperatures.,Study of binding interaction of rivaroxaban with bovine serum albumin using multi-spectroscopic and molecular docking approach. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29260434/),[l] / [mol],1.32 × 105,166403,DB06228,Rivaroxaban
,29260434,binding constants,A decline in the values of binding constants was detected with the increase of temperatures (298-308 K) and the binding constants were in range from 1.32 × 105 to 4.3 × 103 L mol-1 indicating the instability of the BSA and rivaroxaban complex at higher temperatures.,Study of binding interaction of rivaroxaban with bovine serum albumin using multi-spectroscopic and molecular docking approach. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29260434/),[l] / [mol],4.3 × 103,166404,DB06228,Rivaroxaban
,29260434,∆H0,"The ∆G0, ∆H0 and ∆S0 at these temperatures ranged between - 24.67 and - 21.27 kJ mol-1 and the values for ∆H0 and ∆S0 were found to be - 126 kJ mol-1 and ∆S - 340 J mol-1 K-1",Study of binding interaction of rivaroxaban with bovine serum albumin using multi-spectroscopic and molecular docking approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29260434/),[kj] / [mol],-,166405,DB06228,Rivaroxaban
,29260434,∆H0,"The ∆G0, ∆H0 and ∆S0 at these temperatures ranged between - 24.67 and - 21.27 kJ mol-1 and the values for ∆H0 and ∆S0 were found to be - 126 kJ mol-1 and ∆S - 340 J mol-1 K-1",Study of binding interaction of rivaroxaban with bovine serum albumin using multi-spectroscopic and molecular docking approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29260434/),[kj] / [mol],126,166406,DB06228,Rivaroxaban
,29260434,∆S0,"The ∆G0, ∆H0 and ∆S0 at these temperatures ranged between - 24.67 and - 21.27 kJ mol-1 and the values for ∆H0 and ∆S0 were found to be - 126 kJ mol-1 and ∆S - 340 J mol-1 K-1",Study of binding interaction of rivaroxaban with bovine serum albumin using multi-spectroscopic and molecular docking approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29260434/),[kj] / [mol],126,166407,DB06228,Rivaroxaban
,29260434,∆S0,"The ∆G0, ∆H0 and ∆S0 at these temperatures ranged between - 24.67 and - 21.27 kJ mol-1 and the values for ∆H0 and ∆S0 were found to be - 126 kJ mol-1 and ∆S - 340 J mol-1 K-1",Study of binding interaction of rivaroxaban with bovine serum albumin using multi-spectroscopic and molecular docking approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29260434/),[j·k-] / [mol],-,166408,DB06228,Rivaroxaban
,29260434,∆S0,"The ∆G0, ∆H0 and ∆S0 at these temperatures ranged between - 24.67 and - 21.27 kJ mol-1 and the values for ∆H0 and ∆S0 were found to be - 126 kJ mol-1 and ∆S - 340 J mol-1 K-1",Study of binding interaction of rivaroxaban with bovine serum albumin using multi-spectroscopic and molecular docking approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29260434/),[j·k-] / [mol],340,166409,DB06228,Rivaroxaban
,16638738,time to maximum concentration (t(max)),"In the presence of food, time to maximum concentration (t(max)) was delayed by 1.25 hours; maximum concentration (C(max)) and area under the curve (AUC) were increased, with reduced interindividual variability at higher doses of BAY 59-7939.","Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16638738/),h,1.25,170198,DB06228,Rivaroxaban
,16638738,Time to maximum PT,"Time to maximum PT prolongation was delayed by 0.5 to 1.5 hours after food, with no relevant influence of food type.","Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16638738/),h,0.5,170199,DB06228,Rivaroxaban
,16638738,Time to maximum PT,"Time to maximum PT prolongation was delayed by 0.5 to 1.5 hours after food, with no relevant influence of food type.","Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16638738/),h,1.5,170200,DB06228,Rivaroxaban
,33752054,flow rate,"The mobile phase consisted of acetonitrile and 0.01 M ammonium acetate aqueous solution, adjusted to pH 4.4 with acetic acid (26:74, v/v) and it was eluted isocratically at a flow rate of 1.2 mL/min.",HPLC-UV determination of erdafitinib in mouse plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33752054/),[ml] / [min],1.2,171801,DB06228,Rivaroxaban
,33752054,total run time,The UV detection was at 292 nm and the total run time for each sample was 11 min.,HPLC-UV determination of erdafitinib in mouse plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33752054/),min,11,171802,DB06228,Rivaroxaban
,33752054,extraction recoveries,Plasma samples were extracted using a solid phase extraction procedure and the extraction recoveries were 97.90 ± 4.58%.,HPLC-UV determination of erdafitinib in mouse plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33752054/),%,97.90,171803,DB06228,Rivaroxaban
,32633174,C max,The C max (221.34 ± 53.33 vs. 691.18 ± 238.31 ng/mL) and the AUC(0-t) (1060.97 ± 291.21 vs. 3483.03 ± 753.83 μg·h/L) of rivaroxaban increased significantly (p < 0.05) with ticagrelor pre-treatment.,Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32633174/),[ng] / [ml],221.34,172770,DB06228,Rivaroxaban
,32633174,C max,The C max (221.34 ± 53.33 vs. 691.18 ± 238.31 ng/mL) and the AUC(0-t) (1060.97 ± 291.21 vs. 3483.03 ± 753.83 μg·h/L) of rivaroxaban increased significantly (p < 0.05) with ticagrelor pre-treatment.,Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32633174/),[ng] / [ml],691.18,172771,DB06228,Rivaroxaban
,32633174,AUC(0-t),The C max (221.34 ± 53.33 vs. 691.18 ± 238.31 ng/mL) and the AUC(0-t) (1060.97 ± 291.21 vs. 3483.03 ± 753.83 μg·h/L) of rivaroxaban increased significantly (p < 0.05) with ticagrelor pre-treatment.,Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32633174/),[h·μg] / [l],1060.97,172772,DB06228,Rivaroxaban
,32633174,AUC(0-t),The C max (221.34 ± 53.33 vs. 691.18 ± 238.31 ng/mL) and the AUC(0-t) (1060.97 ± 291.21 vs. 3483.03 ± 753.83 μg·h/L) of rivaroxaban increased significantly (p < 0.05) with ticagrelor pre-treatment.,Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32633174/),[h·μg] / [l],3483.03,172773,DB06228,Rivaroxaban
,32633174,MRT(0-∞),"The MRT(0-∞) of rivaroxaban increased from 4.41 ± 0.79 to 5.97 ± 1.11 h, while the intrinsic clearance decreased from 9.93 ± 2.55 to 2.89 ± 0.63 L/h/kg (both p < 0.05) after pre-treated with ticagrelor.",Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32633174/),h,4.41,172774,DB06228,Rivaroxaban
,32633174,MRT(0-∞),"The MRT(0-∞) of rivaroxaban increased from 4.41 ± 0.79 to 5.97 ± 1.11 h, while the intrinsic clearance decreased from 9.93 ± 2.55 to 2.89 ± 0.63 L/h/kg (both p < 0.05) after pre-treated with ticagrelor.",Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32633174/),h,5.97,172775,DB06228,Rivaroxaban
,32633174,intrinsic clearance,"The MRT(0-∞) of rivaroxaban increased from 4.41 ± 0.79 to 5.97 ± 1.11 h, while the intrinsic clearance decreased from 9.93 ± 2.55 to 2.89 ± 0.63 L/h/kg (both p < 0.05) after pre-treated with ticagrelor.",Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32633174/),[l] / [h·kg],9.93,172776,DB06228,Rivaroxaban
,32633174,intrinsic clearance,"The MRT(0-∞) of rivaroxaban increased from 4.41 ± 0.79 to 5.97 ± 1.11 h, while the intrinsic clearance decreased from 9.93 ± 2.55 to 2.89 ± 0.63 L/h/kg (both p < 0.05) after pre-treated with ticagrelor.",Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32633174/),[l] / [h·kg],2.89,172777,DB06228,Rivaroxaban
,32633174,IC50,Enzyme kinetic study indicated that ticagrelor decreased rivaroxaban metabolic clearance with the IC50 value of 14.04 μmol/L.,Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32633174/),[μM] / [l],14.04,172778,DB06228,Rivaroxaban
,29572341,IC50,"The IC50 values of the three PDE5is were 8, 28, and 5 µM for rivaroxaban and 23, 15, and 3 µM for apixaban, respectively.",In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29572341/),μM,8,193385,DB06228,Rivaroxaban
,29572341,IC50,"The IC50 values of the three PDE5is were 8, 28, and 5 µM for rivaroxaban and 23, 15, and 3 µM for apixaban, respectively.",In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29572341/),μM,28,193386,DB06228,Rivaroxaban
,29572341,IC50,"The IC50 values of the three PDE5is were 8, 28, and 5 µM for rivaroxaban and 23, 15, and 3 µM for apixaban, respectively.",In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29572341/),μM,5,193387,DB06228,Rivaroxaban
,29572341,IC50,"The IC50 values of the three PDE5is were 8, 28, and 5 µM for rivaroxaban and 23, 15, and 3 µM for apixaban, respectively.",In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29572341/),μM,23,193388,DB06228,Rivaroxaban
,29572341,IC50,"The IC50 values of the three PDE5is were 8, 28, and 5 µM for rivaroxaban and 23, 15, and 3 µM for apixaban, respectively.",In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29572341/),μM,15,193389,DB06228,Rivaroxaban
,29572341,IC50,"The IC50 values of the three PDE5is were 8, 28, and 5 µM for rivaroxaban and 23, 15, and 3 µM for apixaban, respectively.",In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29572341/),μM,3,193390,DB06228,Rivaroxaban
,27747723,prothrombin time (PT),"The prothrombin time (PT) was prolonged at 24.3 (10.6-15.3) s, and a rivaroxaban level taken 24 h after administration was 75 ng/mL.",Postoperative Bleeding After Administration of a Single Dose of Rivaroxaban to a Patient Receiving Antiretroviral Therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27747723/),s,24.3,196765,DB06228,Rivaroxaban
,30349887,peak concentrations,"The median peak concentrations (IQR) were 148 ng/mL (138-240), 138 ng/mL (123-156.5), 215 ng/mL (181-249) for apixaban, dabigatran, and rivaroxaban, respectively.",Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30349887/),[ng] / [ml],148,199974,DB06228,Rivaroxaban
,30349887,peak concentrations,"The median peak concentrations (IQR) were 148 ng/mL (138-240), 138 ng/mL (123-156.5), 215 ng/mL (181-249) for apixaban, dabigatran, and rivaroxaban, respectively.",Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30349887/),[ng] / [ml],138,199975,DB06228,Rivaroxaban
,30349887,peak concentrations,"The median peak concentrations (IQR) were 148 ng/mL (138-240), 138 ng/mL (123-156.5), 215 ng/mL (181-249) for apixaban, dabigatran, and rivaroxaban, respectively.",Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30349887/),[ng] / [ml],215,199976,DB06228,Rivaroxaban
,30828771,AUC ratios,"Ketoconazole significantly increased exposure, with geometric mean AUC ratios of 1.90 (apixaban), 2.35 (edoxaban) and 2.27 (rivaroxaban).",Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30828771/),,1.90,202533,DB06228,Rivaroxaban
,30828771,AUC ratios,"Ketoconazole significantly increased exposure, with geometric mean AUC ratios of 1.90 (apixaban), 2.35 (edoxaban) and 2.27 (rivaroxaban).",Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30828771/),,2.35,202534,DB06228,Rivaroxaban
,30828771,AUC ratios,"Ketoconazole significantly increased exposure, with geometric mean AUC ratios of 1.90 (apixaban), 2.35 (edoxaban) and 2.27 (rivaroxaban).",Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30828771/),,2.27,202535,DB06228,Rivaroxaban
,32053549,absolute recoveries,"For all 3 anticoagulants and corresponding isotopically labeled internal standards, the absolute recoveries were similar and consistent, with mean values of 93%-102%.","Simultaneous Determination of Dabigatran, Rivaroxaban, and Apixaban in Human Plasma by Liquid Chromatography/Tandem Mass Spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32053549/),%,93,209618,DB06228,Rivaroxaban
,32053549,absolute recoveries,"For all 3 anticoagulants and corresponding isotopically labeled internal standards, the absolute recoveries were similar and consistent, with mean values of 93%-102%.","Simultaneous Determination of Dabigatran, Rivaroxaban, and Apixaban in Human Plasma by Liquid Chromatography/Tandem Mass Spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32053549/),%,102,209619,DB06228,Rivaroxaban
,24861792,time to peak level,"The direct thrombin inhibitor, dabigatran, as well as the direct factor Xa inhibtors rivaroxaban, apixaban, and edoxaban, display pharmacodynamic features quite similar to low-molecular-weight heparins, with a time to peak level of 1-4 hours after oral administration, and a half-life between 5 and 14 hours.","Direct oral anticoagulants--pharmacology, drug interactions, and side effects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861792/),h,1-4,211970,DB06228,Rivaroxaban
,24861792,half-life,"The direct thrombin inhibitor, dabigatran, as well as the direct factor Xa inhibtors rivaroxaban, apixaban, and edoxaban, display pharmacodynamic features quite similar to low-molecular-weight heparins, with a time to peak level of 1-4 hours after oral administration, and a half-life between 5 and 14 hours.","Direct oral anticoagulants--pharmacology, drug interactions, and side effects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861792/),h,5 and 14,211971,DB06228,Rivaroxaban
,24861792,re,"Major differences are the extent of renal elimination (with 80% or more for dabigatran, 66% for rivaroxaban [33% unchanged, active drug, and 33% inactive metabolites], 33% for edoxaban, and finally, 25% for apixaban), and bioavailability, which determines the amount of drug required for attaining the target plasma concentration of the drug.","Direct oral anticoagulants--pharmacology, drug interactions, and side effects. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861792/),%,66,211972,DB06228,Rivaroxaban
,24861792,re,"Major differences are the extent of renal elimination (with 80% or more for dabigatran, 66% for rivaroxaban [33% unchanged, active drug, and 33% inactive metabolites], 33% for edoxaban, and finally, 25% for apixaban), and bioavailability, which determines the amount of drug required for attaining the target plasma concentration of the drug.","Direct oral anticoagulants--pharmacology, drug interactions, and side effects. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861792/),%,33,211973,DB06228,Rivaroxaban
,24861792,re,"Major differences are the extent of renal elimination (with 80% or more for dabigatran, 66% for rivaroxaban [33% unchanged, active drug, and 33% inactive metabolites], 33% for edoxaban, and finally, 25% for apixaban), and bioavailability, which determines the amount of drug required for attaining the target plasma concentration of the drug.","Direct oral anticoagulants--pharmacology, drug interactions, and side effects. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861792/),%,25,211974,DB06228,Rivaroxaban
,32920985,C0h /D,The median (quartile range) rivaroxaban C0h /D was 3.39 (2.08-5.21) ng/mL/mg (coefficient of variation: 80.5%).,Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32920985/),[ng] / [mg·ml],3.39,218931,DB06228,Rivaroxaban
,23417780,Peak concentrations,Peak concentrations of 224.22 ng/ml were observed.,Pharmacokinetics of rivaroxaban after bariatric surgery: a case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417780/),[ng] / [ml],224.22,226358,DB06228,Rivaroxaban
,23417780,plasma concentration,"After 6 h, plasma concentration decreased to 86.9 ng/ml and remained stable until 12 h (86.32 ng/ml).",Pharmacokinetics of rivaroxaban after bariatric surgery: a case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417780/),[ng] / [ml],86.9,226359,DB06228,Rivaroxaban
,23417780,plasma concentration,"After 6 h, plasma concentration decreased to 86.9 ng/ml and remained stable until 12 h (86.32 ng/ml).",Pharmacokinetics of rivaroxaban after bariatric surgery: a case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417780/),[ng] / [ml],86.32,226360,DB06228,Rivaroxaban
,23417780,trough level,"After 24 h, a trough level of 35.54 ng/ml was observed.",Pharmacokinetics of rivaroxaban after bariatric surgery: a case report. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417780/),[ng] / [ml],35.54,226361,DB06228,Rivaroxaban
,32007354,AUC,"The geometric mean AUC for the 0 to 24-h interval was 4550 ng h/mL for apixaban, 2710 ng h/mL for 15 mg QD rivaroxaban, and 1290 ng h/mL for 60 mg QD edoxaban.",Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32007354/),[h·ng] / [ml],4550,228919,DB06228,Rivaroxaban
,32007354,AUC,"The geometric mean AUC for the 0 to 24-h interval was 4550 ng h/mL for apixaban, 2710 ng h/mL for 15 mg QD rivaroxaban, and 1290 ng h/mL for 60 mg QD edoxaban.",Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32007354/),[h·ng] / [ml],2710,228920,DB06228,Rivaroxaban
,32007354,AUC,"The geometric mean AUC for the 0 to 24-h interval was 4550 ng h/mL for apixaban, 2710 ng h/mL for 15 mg QD rivaroxaban, and 1290 ng h/mL for 60 mg QD edoxaban.",Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32007354/),[h·ng] / [ml],1290,228921,DB06228,Rivaroxaban
,32438078,Ctrough,"In 8 renal transplant patients, rivaroxaban levels showed a predictable pharmacokinetic trend, both at Ctrough (30-61 μg/L) and at Cpeak (143-449 μg/L), with limited variability in the 25th-75th percentile range.","Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438078/),[μg] / [l],30-61,235704,DB06228,Rivaroxaban
,32438078,Cpeak,"In 8 renal transplant patients, rivaroxaban levels showed a predictable pharmacokinetic trend, both at Ctrough (30-61 μg/L) and at Cpeak (143-449 μg/L), with limited variability in the 25th-75th percentile range.","Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438078/),[μg] / [l],143-449,235705,DB06228,Rivaroxaban
,32438078,Ctrough,"Tacrolimus (Ctrough 3-13 μg/L; Cpeak 3-16 μg/L), everolimus (Ctrough 3-11 μg/L; Cpeak 5-17 μg/L) and creatinine concentrations were stable as well.","Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438078/),[μg] / [l],3-13,235706,DB06228,Rivaroxaban
,32438078,Cpeak,"Tacrolimus (Ctrough 3-13 μg/L; Cpeak 3-16 μg/L), everolimus (Ctrough 3-11 μg/L; Cpeak 5-17 μg/L) and creatinine concentrations were stable as well.","Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438078/),[μg] / [l],3-16,235707,DB06228,Rivaroxaban
,32438078,Ctrough,"Tacrolimus (Ctrough 3-13 μg/L; Cpeak 3-16 μg/L), everolimus (Ctrough 3-11 μg/L; Cpeak 5-17 μg/L) and creatinine concentrations were stable as well.","Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438078/),[μg] / [l],3-11,235708,DB06228,Rivaroxaban
,32438078,Cpeak,"Tacrolimus (Ctrough 3-13 μg/L; Cpeak 3-16 μg/L), everolimus (Ctrough 3-11 μg/L; Cpeak 5-17 μg/L) and creatinine concentrations were stable as well.","Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438078/),[μg] / [l],5-17,235709,DB06228,Rivaroxaban
> or =,19196845,Recovery,Recovery of total radioactivity was high and > or = 92% in all species.,"Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19196845/),%,92,240593,DB06228,Rivaroxaban
,19196845,urinary excretion of radio,"Rivaroxaban and its metabolites were rapidly excreted; urinary excretion of radioactivity was 25 and 52%, and fecal excretion was 67 and 43% of the dose in rats and dogs, respectively.","Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19196845/),%,25,240594,DB06228,Rivaroxaban
,19196845,urinary excretion of radio,"Rivaroxaban and its metabolites were rapidly excreted; urinary excretion of radioactivity was 25 and 52%, and fecal excretion was 67 and 43% of the dose in rats and dogs, respectively.","Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19196845/),%,52,240595,DB06228,Rivaroxaban
,19196845,fecal excretion,"Rivaroxaban and its metabolites were rapidly excreted; urinary excretion of radioactivity was 25 and 52%, and fecal excretion was 67 and 43% of the dose in rats and dogs, respectively.","Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19196845/),%,67,240596,DB06228,Rivaroxaban
,19196845,fecal excretion,"Rivaroxaban and its metabolites were rapidly excreted; urinary excretion of radioactivity was 25 and 52%, and fecal excretion was 67 and 43% of the dose in rats and dogs, respectively.","Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19196845/),%,43,240597,DB06228,Rivaroxaban
,33356742,zeta potential,"The selected formulation (RVX-TFL2) composed of PL S100/Tween 80 (85/15% w/w) and coated with CS solution in the strength of (0.2% w/v) had a particle size of 105.67 nm, a zeta potential of +5.67 mV and EE of 96.07%.",Chitosan caged liposomes for improving oral bioavailability of rivaroxaban: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33356742/),m,5.67,242287,DB06228,Rivaroxaban
,33356742,EE,"The selected formulation (RVX-TFL2) composed of PL S100/Tween 80 (85/15% w/w) and coated with CS solution in the strength of (0.2% w/v) had a particle size of 105.67 nm, a zeta potential of +5.67 mV and EE of 96.07%.",Chitosan caged liposomes for improving oral bioavailability of rivaroxaban: in vitro and in vivo evaluation. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33356742/),%,96.07,242288,DB06228,Rivaroxaban
,33356742,bioavailability,"Besides, RVX bioavailability with RVX-TFL2 was improved by 59.66% and 26.97% in the fed and fasted states, respectively, compared to RVX suspension in the fed state.",Chitosan caged liposomes for improving oral bioavailability of rivaroxaban: in vitro and in vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33356742/),%,59.66,242289,DB06228,Rivaroxaban
,33356742,bioavailability,"Besides, RVX bioavailability with RVX-TFL2 was improved by 59.66% and 26.97% in the fed and fasted states, respectively, compared to RVX suspension in the fed state.",Chitosan caged liposomes for improving oral bioavailability of rivaroxaban: in vitro and in vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33356742/),%,26.97,242290,DB06228,Rivaroxaban
,19660005,time to C(max),Rapid absorption was observed in both studies (time to C(max) 1.25-2.5 h).,"Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19660005/),h,1.25-2.5,242399,DB06228,Rivaroxaban
up to,19660005,half-life,The half-life of rivaroxaban was up to 7.9 h in the single-dose study.,"Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19660005/),h,7.9,242400,DB06228,Rivaroxaban
,25880707,peak plasma concentrations,"When the patient was instructed to take rivaroxaban with a regular meal, peak plasma concentrations increased from 115 to 318 ng mL(-1) (+ 176%).",Of men and meals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25880707/),[ng] / [ml],115,247531,DB06228,Rivaroxaban
,25880707,peak plasma concentrations,"When the patient was instructed to take rivaroxaban with a regular meal, peak plasma concentrations increased from 115 to 318 ng mL(-1) (+ 176%).",Of men and meals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25880707/),[ng] / [ml],31,247532,DB06228,Rivaroxaban
,25880707,peak plasma concentrations,"When the patient was instructed to take rivaroxaban with a regular meal, peak plasma concentrations increased from 115 to 318 ng mL(-1) (+ 176%).",Of men and meals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25880707/),[ng] / [ml],8,247533,DB06228,Rivaroxaban
,27105920,flow rate,"Both TDZ and IS were separated on an Acquity UPLC BEH™ C18 column using an isocratic mobile phase comprising of acetonitrile-20 mm ammonium acetate (85:15, v/v), eluted at 0.3 mL/min flow rate.",A highly sensitive and efficient UPLC-MS/MS assay for rapid analysis of tedizolid (a novel oxazolidinone antibiotic) in plasma sample. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27105920/),[ml] / [min],0.3,265249,DB06228,Rivaroxaban
>,27105920,m/z,The precursor to product ion transitions at m/z 371.09 > 343.10 for TDZ and m/z 435.97 > 144.94 for IS were used for the quantification in multiple reaction monitoring mode.,A highly sensitive and efficient UPLC-MS/MS assay for rapid analysis of tedizolid (a novel oxazolidinone antibiotic) in plasma sample. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27105920/),,371.09,265250,DB06228,Rivaroxaban
>,27105920,m/z,The precursor to product ion transitions at m/z 371.09 > 343.10 for TDZ and m/z 435.97 > 144.94 for IS were used for the quantification in multiple reaction monitoring mode.,A highly sensitive and efficient UPLC-MS/MS assay for rapid analysis of tedizolid (a novel oxazolidinone antibiotic) in plasma sample. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27105920/),,343.10,265251,DB06228,Rivaroxaban
>,27105920,m/z,The precursor to product ion transitions at m/z 371.09 > 343.10 for TDZ and m/z 435.97 > 144.94 for IS were used for the quantification in multiple reaction monitoring mode.,A highly sensitive and efficient UPLC-MS/MS assay for rapid analysis of tedizolid (a novel oxazolidinone antibiotic) in plasma sample. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27105920/),,435.97,265252,DB06228,Rivaroxaban
>,27105920,m/z,The precursor to product ion transitions at m/z 371.09 > 343.10 for TDZ and m/z 435.97 > 144.94 for IS were used for the quantification in multiple reaction monitoring mode.,A highly sensitive and efficient UPLC-MS/MS assay for rapid analysis of tedizolid (a novel oxazolidinone antibiotic) in plasma sample. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27105920/),,144.94,265253,DB06228,Rivaroxaban
,28805299,area under the plasma concentration-time curve,Results Overall exposure was similar for both drugs: the geometric mean area under the plasma concentration-time curve for the 0-24-h interval was 1830 μg h L-1 for rivaroxaban and 1860 μg h L-1 for apixaban.,Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28805299/),[h·μg] / [l],1830,265908,DB06228,Rivaroxaban
,28805299,area under the plasma concentration-time curve,Results Overall exposure was similar for both drugs: the geometric mean area under the plasma concentration-time curve for the 0-24-h interval was 1830 μg h L-1 for rivaroxaban and 1860 μg h L-1 for apixaban.,Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28805299/),[h·μg] / [l],1860,265909,DB06228,Rivaroxaban
,28805299,area under the curve,Rivaroxaban was associated with greater inhibition of endogenous thrombin potential (geometric mean area under the curve relative to baseline during the 0-24-h interval: 15.5 h versus 17.5 h) and a more pronounced maximal prolongation relative to baseline of prothrombin time (PT) (1.66-fold versus 1.14-fold) and activated partial thromboplastin time (APTT) (1.43-fold versus 1.16-fold) at steady state than apixaban.,Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28805299/),h,15.5,265910,DB06228,Rivaroxaban
,28805299,area under the curve,Rivaroxaban was associated with greater inhibition of endogenous thrombin potential (geometric mean area under the curve relative to baseline during the 0-24-h interval: 15.5 h versus 17.5 h) and a more pronounced maximal prolongation relative to baseline of prothrombin time (PT) (1.66-fold versus 1.14-fold) and activated partial thromboplastin time (APTT) (1.43-fold versus 1.16-fold) at steady state than apixaban.,Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28805299/),h,17.5,265911,DB06228,Rivaroxaban
,34256392,concentration,Median concentration on admission was 205 ng/mL for rivaroxaban and 108 ng/mL for apixaban.,Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256392/),[ng] / [ml],205,269424,DB06228,Rivaroxaban
,34256392,concentration,Median concentration on admission was 205 ng/mL for rivaroxaban and 108 ng/mL for apixaban.,Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256392/),[ng] / [ml],108,269425,DB06228,Rivaroxaban
,34256392,t ½,"In rivaroxaban-treated patients t ½ was 17.3 hours (95% confidence interval [CI]: 15.4-19.7) without significant difference in both groups (major bleeding: t ½ 16.7 hours, 95% CI: 14.7-19.3; urgent surgery: t ½ 19.7 hours, 95% CI: 15.2-27.9; p = 0.292).",Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256392/),h,17.3,269426,DB06228,Rivaroxaban
,34256392,t ½,"In rivaroxaban-treated patients t ½ was 17.3 hours (95% confidence interval [CI]: 15.4-19.7) without significant difference in both groups (major bleeding: t ½ 16.7 hours, 95% CI: 14.7-19.3; urgent surgery: t ½ 19.7 hours, 95% CI: 15.2-27.9; p = 0.292).",Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256392/),h,16.7,269427,DB06228,Rivaroxaban
,34256392,t ½,"In rivaroxaban-treated patients t ½ was 17.3 hours (95% confidence interval [CI]: 15.4-19.7) without significant difference in both groups (major bleeding: t ½ 16.7 hours, 95% CI: 14.7-19.3; urgent surgery: t ½ 19.7 hours, 95% CI: 15.2-27.9; p = 0.292).",Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256392/),h,19.7,269428,DB06228,Rivaroxaban
,34256392,t ½,In apixaban-treated patients t ½ was 25.0 hours (95% CI: 22.9-27.6) with a longer t ½ after urgent surgery (t 1/2: 30.8 hours; 95% CI: 26.9-36.4) compared with severe bleeding (t 1/2: 20.8 hours; 95% CI: 18.8-23.2; p < 0.001).,Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256392/),h,25.0,269429,DB06228,Rivaroxaban
,34256392,t 1/2,In apixaban-treated patients t ½ was 25.0 hours (95% CI: 22.9-27.6) with a longer t ½ after urgent surgery (t 1/2: 30.8 hours; 95% CI: 26.9-36.4) compared with severe bleeding (t 1/2: 20.8 hours; 95% CI: 18.8-23.2; p < 0.001).,Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256392/),h,30.8,269430,DB06228,Rivaroxaban
,34256392,t 1/2,In apixaban-treated patients t ½ was 25.0 hours (95% CI: 22.9-27.6) with a longer t ½ after urgent surgery (t 1/2: 30.8 hours; 95% CI: 26.9-36.4) compared with severe bleeding (t 1/2: 20.8 hours; 95% CI: 18.8-23.2; p < 0.001).,Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256392/),h,20.8,269431,DB06228,Rivaroxaban
,30918237,peak PC,A total of 73 off-label under-dose users of rivaroxaban (37% of all users and 63% of lower dose users) had acceptable peak PC (155-400 ng/mL).,Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation - Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30918237/),[ng] / [ml],155-400,270029,DB06228,Rivaroxaban
,30918237,peak PC threshold,"Additionally, 46 off-label under-dose users of apixaban (31% of all users and 55% of lower dose users) received appropriate doses according to peak PC threshold (90-386.4 ng/mL).",Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation - Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30918237/),[ng] / [ml],90-386.4,270030,DB06228,Rivaroxaban
